Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
20–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
\[Dose Escalation Part\]
Histological or cytological diagnosis of locally advanced or metastatic solid tumor that is resistant to standard therapy or for which no standard therapy is available.
ECOG Performance Status 0 or 1.
Adequate Bone Marrow, Renal and Liver Function.
Histologically or cytologically confirmed carcinoma of the breast.
Locally advanced breast cancer that is not amenable to curative radiation or surgery and/or metastatic disease.
Documentation of a deleterious, suspected deleterious, or pathogenic germline BRCA1 or BRCA2 mutation by Myriad Genetics' BRACAnalysis CDx test.
No more than 3 prior chemotherapy-inclusive regimens for locally advanced or metastatic disease.
Have measurable lesion by the RECIST v.1.1.
ECOG Performance Status 0-2.
Adequate Bone Marrow, Renal and Liver Function.
You may not be if
Patients with known symptomatic brain metastases requiring steroids.
Current use of a strong P-gp inhibitor, strong P-gp inducer, or strong inhibitor of BCRP within 1 week or 5 half lives which ever is longer prior to the first dose of study treatment.
Fertile male patients and female patients of childbearing potential who are unwilling or unable to use 2 highly effective methods of contraception.
\[Dose Expansion Part\]
First-line locally advanced or metastatic breast cancer with no prior neoadjuvant and adjuvant chemotherapy.
Prior treatment with a PARP inhibitor.
Objective disease progression while receiving platinum chemotherapy administered for locally advanced or metastatic disease.
HER2 positive breast cancer.
Active inflammatory breast cancer.
Central nervous system (CNS) metastases.
Current or anticipated use within 7 days prior to the first dose of study treatment, or anticipated use during the study of strong P-gp inhibitors.
Fertile male patients and female patients of childbearing potential who are unwilling or unable to use 2 highly effective methods of contraception.
Clareo Health | A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors
